How to get off Wegovy and not gain weight

Why the body tends to regain weight after stopping, and what the trial data shows

The STEP 1 extension study — following participants from the main semaglutide 2.4mg trial after they stopped treatment — found that average body weight returned to within a few percentage points of its pre-treatment level within 52 weeks of stopping. The mechanism is well understood: semaglutide works by signalling fullness and slowing gastric emptying, and when it leaves the body those signals diminish. Appetite returns, energy expenditure adjusts downward, and the biological factors that drove excess weight in the first place are still present.

This is not a failure of willpower. UK NICE guidance on semaglutide (TA875) explicitly frames obesity as a chronic condition rather than a short-term problem to be fixed and finished. Understanding that framing matters, because it changes how you plan your exit. Stopping abruptly with no structure in place is the scenario most likely to result in rapid regain. Stopping with a clear plan is a different story.

The practical takeaway from the evidence is that the work you do in the months before stopping matters at least as much as the stopping itself. Protein intake, resistance training, sleep quality and a sustainable calorie intake are all documented influences on weight maintenance. Your prescriber can help you build that structure; the NHS Better Health programme also offers free UK tools and support that many people find useful alongside clinical care.

What stopping Wegovy looks like in practice, and why a step-down matters

Stopping semaglutide the week the pen runs out, with no transition, is the highest-risk approach. Most UK prescribers, including those at our clinical team, will discuss a structured step-down where clinically appropriate: reducing the dose gradually rather than cutting from 2.4mg to zero, which gives the body and appetite more time to adjust. Not every patient needs this, and not everyone is at the same dose when they decide to stop, so the conversation is individual.

If stopping is driven by side effects rather than a planned exit, that is a different clinical situation altogether. Severe gastrointestinal symptoms, persistent nausea or a symptom that worries you is a reason to contact your prescriber, not quietly stop. The NHS England guidance on weight-management injections is clear that these medicines should be used with ongoing clinical support, and that decisions about continuation, dose and stopping are made with a prescriber.

For people wondering whether a short break, rather than a full stop, is possible, the answer depends on clinical context. Some prescribers will support a planned pause, for example around surgery or a planned pregnancy; others will recommend a switch rather than a gap. The detail on stopping semaglutide covers this in full. The point is that a pause without medical input is not the same as a clinically planned pause.

Switching to a different treatment instead of stopping completely

For many people, stopping entirely is not the right move. The evidence for continued treatment is strong, and some patients who cannot tolerate Wegovy at higher doses, or who have plateaued, are better served by switching to a different licensed medicine than by stopping altogether. Tirzepatide (Mounjaro) is the other GLP-1 class medicine licensed in the UK for weight management, with a dual mechanism that some people respond to differently. Patients considering a switch often ask whether they can start a new course or transition directly, and the clinical answer depends on where they are in their current treatment and their health profile.

Transfer patients coming to a new pharmacy should expect evidence checks before a dose change is approved. At nume, a prescriber reviews transfer requests individually rather than simply matching the dose on a previous label. That is not bureaucracy for its own sake; it reflects what responsible clinical practice looks like for prescription-only medicines. The full Wegovy overview explains what to expect at each stage, and the access guide, which walks through what a legitimate private prescription process involves, covers what to expect from a compliant UK supplier.

How to verify any pharmacy you use, and why it matters here

If you are considering stopping or switching and plan to use a private online pharmacy, the legitimacy of that pharmacy is not a small detail. The MHRA has issued repeated warnings about counterfeit weight-loss pens sold online, including pens that have contained insulin rather than semaglutide, reportable to the Yellow Card scheme if encountered. Any pharmacy supplying Wegovy or Mounjaro in the UK must hold a valid GPhC registration, verifiable at the GPhC register. Sellers offering these medicines without a clinical assessment, or at prices far below the UK market rate, are a red flag regardless of how professional their website looks.

Timing is worth thinking about too: if you are approaching a bank holiday or heading away and your prescription is about to lapse, getting a clinical review booked on a regular Monday rather than a scramble before a holiday is the calm version. The common questions section covers supply timing in more detail, and if your situation is unusual, such as wondering whether Wegovy is accessible to people who fall outside the standard weight thresholds, that is also addressed there. If you are ready to discuss your next steps with a prescriber, you can read about how to get Wegovy through a UK clinical pathway before booking, and the free consultation takes a few minutes and is reviewed the same day.